Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of weekly docetaxel + carboplatin/cisplatin + cetuximab (DCC) in advanced squamous cell carcinoma of the oropharynx and oral cavity
2007-007034-18Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, carboplatin, cisplatin and cetuximab in oropharyngeal squamous cell carcinoma (OPSCC) and Oral Mucosal Carcinoma, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: time to progression and tumor response. Started Aug 2008; status: completed.
02
Drugs
docetaxelcarboplatincisplatincetuximab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2007-007034-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007034-18.